Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PCYC's Cash to Debt is ranked higher than
85% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. PCYC: No Debt )
PCYC' s 10-Year Cash to Debt Range
Min: 0.1   Max: 26993.8
Current: No Debt

0.1
26993.8
Equity to Asset 0.83
PCYC's Equity to Asset is ranked higher than
87% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. PCYC: 0.83 )
PCYC' s 10-Year Equity to Asset Range
Min: 0.6   Max: 0.98
Current: 0.83

0.6
0.98
Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
96% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. PCYC: No Debt )
PCYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 34.94
M-Score: -1.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 37.64
PCYC's Operating margin (%) is ranked higher than
98% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. PCYC: 37.64 )
PCYC' s 10-Year Operating margin (%) Range
Min: -24376.8   Max: 37.64
Current: 37.64

-24376.8
37.64
Net-margin (%) 25.76
PCYC's Net-margin (%) is ranked higher than
96% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. PCYC: 25.76 )
PCYC' s 10-Year Net-margin (%) Range
Min: -23291.71   Max: 25.76
Current: 25.76

-23291.71
25.76
ROE (%) 10.68
PCYC's ROE (%) is ranked higher than
83% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PCYC: 10.68 )
PCYC' s 10-Year ROE (%) Range
Min: -147.75   Max: 10.68
Current: 10.68

-147.75
10.68
ROA (%) 8.72
PCYC's ROA (%) is ranked higher than
89% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. PCYC: 8.72 )
PCYC' s 10-Year ROA (%) Range
Min: -300   Max: 8.72
Current: 8.72

-300
8.72
ROC (Joel Greenblatt) (%) 227.66
PCYC's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. PCYC: 227.66 )
PCYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5775.13   Max: 309.16
Current: 227.66

-5775.13
309.16
Revenue Growth (%) 161.00
PCYC's Revenue Growth (%) is ranked higher than
99% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. PCYC: 161.00 )
PCYC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 166.8
Current: 161

0
166.8
» PCYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PCYC Guru Trades in Q3 2013

Murray Stahl 2,801 sh (New)
Jim Simons 285,500 sh (New)
Mariko Gordon 1,902 sh (New)
PRIMECAP Management 2,381,239 sh (-2.42%)
Steven Cohen 401,796 sh (-19.31%)
» More
Q4 2013

PCYC Guru Trades in Q4 2013

Steven Cohen 939,713 sh (+133.88%)
Mariko Gordon 4,376 sh (+130.07%)
Murray Stahl 5,075 sh (+81.19%)
Mariko Gordon 5,300 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 2,380,739 sh (-0.02%)
» More
Q1 2014

PCYC Guru Trades in Q1 2014

Joel Greenblatt 9,591 sh (New)
Jim Simons 47,700 sh (New)
Mariko Gordon 9,295 sh (+112.41%)
Murray Stahl 6,864 sh (+35.25%)
PRIMECAP Management 2,380,739 sh (unchged)
Steven Cohen 388,523 sh (-58.66%)
» More
Q2 2014

PCYC Guru Trades in Q2 2014

Ken Fisher 5,114 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2014-03-31 Add 112.41%0.02%$100.49 - $151.61 $ 108.5-16%9295
Joel Greenblatt 2014-03-31 New Buy0.01%$100.49 - $151.61 $ 108.5-16%9591
Mariko Gordon 2013-12-31 Add 130.07%0.01%$99.28 - $139.59 $ 108.5-11%4376
Mariko Gordon 2013-09-30 New Buy0.01%$84.5 - $132.49 $ 108.5-2%1902
Joel Greenblatt 2013-03-31 Sold Out 0.14%$57.78 - $94.2 $ 108.540%0
Joel Greenblatt 2012-12-31 New Buy0.14%$47.87 - $69.78 $ 108.585%41832
George Soros 2012-06-30 Sold Out 0.04%$25.72 - $53.44 $ 108.5233%0
George Soros 2012-03-31 New Buy0.04%$14.99 - $28.68 $ 108.5419%100000
PRIMECAP Management 2011-06-30 Add 21.34%0.01%$5.66 - $10.63 $ 108.51413%4011958
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Pharmacyclics Inc

Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Blackstone Group LP, Pharmacyclics Inc., Masco Corporation and InterMune Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 70.60
PCYC's P/E(ttm) is ranked higher than
70% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. PCYC: 70.60 )
PCYC' s 10-Year P/E(ttm) Range
Min: 35.9   Max: 496.74
Current: 70.6

35.9
496.74
P/B 14.00
PCYC's P/B is ranked lower than
52% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. PCYC: 14.00 )
PCYC' s 10-Year P/B Range
Min: 0.24   Max: 35.11
Current: 14

0.24
35.11
P/S 25.90
PCYC's P/S is ranked lower than
51% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. PCYC: 25.90 )
PCYC' s 10-Year P/S Range
Min: 10.87   Max: 617
Current: 25.9

10.87
617
PFCF 74.80
PCYC's PFCF is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PCYC: 74.80 )
PCYC' s 10-Year PFCF Range
Min: 8.05   Max: 218.11
Current: 74.8

8.05
218.11
EV-to-EBIT 42.06
PCYC's EV-to-EBIT is ranked higher than
71% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. PCYC: 42.06 )
PCYC' s 10-Year EV-to-EBIT Range
Min: 24   Max: 400.3
Current: 42.06

24
400.3
Shiller P/E 1074.20
PCYC's Shiller P/E is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PCYC: 1074.20 )
PCYC' s 10-Year Shiller P/E Range
Min: 717.58   Max: 7580.5
Current: 1074.2

717.58
7580.5
Current Ratio 8.12
PCYC's Current Ratio is ranked higher than
93% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. PCYC: 8.12 )
PCYC' s 10-Year Current Ratio Range
Min: 0.14   Max: 49.32
Current: 8.12

0.14
49.32
Quick Ratio 7.82
PCYC's Quick Ratio is ranked higher than
93% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. PCYC: 7.82 )
PCYC' s 10-Year Quick Ratio Range
Min: 0.14   Max: 49.32
Current: 7.82

0.14
49.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.80
PCYC's Price/Net Cash is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PCYC: 14.80 )
PCYC' s 10-Year Price/Net Cash Range
Min: 0.46   Max: 1650
Current: 14.8

0.46
1650
Price/Net Current Asset Value 13.90
PCYC's Price/Net Current Asset Value is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PCYC: 13.90 )
PCYC' s 10-Year Price/Net Current Asset Value Range
Min: 0.46   Max: 825
Current: 13.9

0.46
825
Price/Tangible Book 12.20
PCYC's Price/Tangible Book is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PCYC: 12.20 )
PCYC' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 28.59
Current: 12.2

0.44
28.59
Price/DCF (Projected) 9.00
PCYC's Price/DCF (Projected) is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PCYC: 9.00 )
PCYC' s 10-Year Price/DCF (Projected) Range
Min: 7.45   Max: 236.31
Current: 9

7.45
236.31
Price/Median PS Value 0.30
PCYC's Price/Median PS Value is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. PCYC: 0.30 )
PCYC' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 13.17
Current: 0.3

0.2
13.17
Price/Graham Number 5.70
PCYC's Price/Graham Number is ranked higher than
67% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. PCYC: 5.70 )
PCYC' s 10-Year Price/Graham Number Range
Min: 3.73   Max: 20.08
Current: 5.7

3.73
20.08
Earnings Yield (Greenblatt) 2.10
PCYC's Earnings Yield (Greenblatt) is ranked higher than
57% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. PCYC: 2.10 )
PCYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4.2
Current: 2.1

0.2
4.2
Forward Rate of Return (Yacktman) 0.19
PCYC's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. PCYC: 0.19 )
PCYC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.2   Max: 0.3
Current: 0.19

-6.2
0.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PY2.Germany
Pharmacyclics, Inc. was incorporated in Delaware in 1991 and commenced operations in 1992. It is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's corporate mission statement reads as follows: To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs; To identify promising product candidates based on exceptional scientific development expertise, develop its products in a cost-efficient manner and to pursue commercialization and/or development partners when and where appropriate. Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs toward potential commercialization. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It currently has three proprietary drug candidates under clinical development and several preclinical lead molecules. These include: an inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib (PCI-32765, hereafter referred to as ibrutinib) currently initiating Phase III studies in hematologic malignancies, a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer and a HDAC inhibitor abexinostat (formerly known as PCI-24781) currently in Phase I and II clinical trials in solid tumors and hematological malignancies. It uses third parties to manufacture various components of its products under development. The Company owns or controls granted patents in the U.S., Europe, Japan and Australia, that claim the ibrutinib compound and related BTK inhibitor compounds as compositions of matter. It faces intense competition for each of its drug targets from pharmaceutical companies, universities, governmental entities and others in the development of therapeutic and diagnostic agents for the treatment of diseases. It is subject to regulation by federal, state and other authorities within the United States and numerous entities outside of the United States.
» More Articles for PCYC

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
comment on PCYC Mar 06 2013 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Feb 08 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Weekly CEO Buys Highlight: Pharmacyclics Inc, Saul Centers Inc, Charming Shoppes Inc, ProLogis, Exce Jun 27 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) May 07 2010 
cooldecency99 note on PCYC May 01 2010 
cooldecency99 note on PCYC May 01 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 03 2009 


More From Other Websites
Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of... Jul 28 2014
Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of... Jul 28 2014
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Jul 28 2014
U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications Jul 28 2014
1:19 pm Pharmacyclics: FDA grants regular full approval for IMBRUVICA for two indications Jul 28 2014
U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications Jul 28 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA®... Jul 25 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA®... Jul 25 2014
Europe backs new leukaemia drugs from J&J and Gilead Jul 25 2014
Can the Rally in Pharmacyclics (PCYC) Shares Continue? Jul 24 2014
[video] Upside ahead for Vertex: Pro Jun 24 2014
Pharmacyclics' Imbruvica Under FDA Priority Review Jun 10 2014
Pharmacyclics Jun 09 2014
Pharmacyclics reports sNDA for Imbruvica accepted, priority review granted Jun 09 2014
Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review... Jun 09 2014
PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower Jun 06 2014
PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide